Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study

Journal of Clinical Pharmacology
Craig BoultonRobert Schmouder

Abstract

Fingolimod, a first-in-class oral sphingosine 1-phosphate receptor (S1PR) modulator, is approved in many countries for relapsing-remitting multiple sclerosis, at a once-daily 0.5-mg dose. A reduction in peripheral lymphocyte count is an expected consequence of the fingolimod mechanism of S1PR modulation. The authors investigated if this pharmacodynamic effect impacts humoral and cellular immunogenicity. In this double-blind, parallel-group, 4-week study, 72 healthy volunteers were randomized to steady state, fingolimod 0.5 mg, 1.25 mg, or to placebo. The authors compared T-cell dependent and independent responses to the neoantigens, keyhole limpet hemocyanin (KLH), and pneumococcal polysaccharides vaccine (PPV-23), respectively, and additionally recall antigen response (tetanus toxoid [TT]) and delayed-type hypersensitivity (DTH) to KLH, TT, and Candida albicans. Fingolimod caused mild to moderate decreases in anti-KLH and anti-PPV-23 IgG and IgM levels versus placebo. Responder rates were identical between placebo and 0.5-mg groups for anti-KLH IgG (both > 90%) and comparable for anti-PPV-23 IgG (55% and 41%, respectively). Fingolimod did not affect anti-TT immunogenicity, and DTH response did not differ between placebo and fi...Continue Reading

References

May 23, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·D D PinschewerR M Zinkernagel
Jul 7, 2000·The New England Journal of Medicine·P J Delves, I M Roitt
Jul 13, 2000·The New England Journal of Medicine·P J Delves, I M Roitt
Oct 30, 2003·The Cochrane Database of Systematic Reviews·K DearD Tatham
Mar 23, 2004·Annual Review of Immunology·Federica SallustoAntonio Lanzavecchia
Apr 20, 2004·British Journal of Clinical Pharmacology·John M KovarikGerolf Kraus
Apr 23, 2004·Journal of Clinical Pharmacology·John M KovarikThomas Hunt
Jul 21, 2005·Vaccine·Manuela MenzelLoems Ziegler-Heitbrock
Nov 24, 2005·Clinical Medicine & Research·Joseph J MazzaKurt D Reed
Dec 13, 2006·International Immunopharmacology·Matthias HofmannHans-Günter Zerwes
Jan 12, 2010·Clinical Neuropharmacology·Jerold Chun, Hans-Peter Hartung
Jan 22, 2010·The New England Journal of Medicine·Ludwig KapposUNKNOWN FREEDOMS Study Group
Jan 22, 2010·The New England Journal of Medicine·Jeffrey A CohenUNKNOWN TRANSFORMS Study Group

❮ Previous
Next ❯

Citations

Apr 1, 2014·Journal of Neuroimmunology·Achilles NtranosAnne R Gocke
May 17, 2014·British Journal of Clinical Pharmacology·Ashwin SwaminathanAnthony J McMichael
Feb 29, 2016·Current Neurology and Neuroscience Reports·Eric M L WilliamsonJoseph R Berger
Oct 14, 2014·Frontiers in Cellular Neuroscience·Robert BrunkhorstWaltraud Pfeilschifter
Nov 17, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicolas PoirierBernard Vanhove
Oct 10, 2012·Nature Reviews. Neurology·Markus KrumbholzEdgar Meinl
Sep 29, 2017·Neurology. Neuroimmunology and Neuroinflammation·Mike UferEric Legangneux
Feb 9, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Johanna E HuberDirk Baumjohann
Sep 18, 2020·Multiple Sclerosis : Clinical and Laboratory Research·Lucia MoiolaAgostino Riva
Jul 8, 2020·Practical Neurology·Saúl ReyesG Giovannoni
Apr 9, 2021·Science Translational Medicine·Julia P VainonenJukka Westermarck
May 1, 2019·Revue neurologique·C LebrunUNKNOWN French Group for Recommendations in Multiple Sclerosis (France4MS), the Société francophone de la sclérose en plaques (SFSEP
Jun 5, 2019·Multiple Sclerosis and Related Disorders·Christine LebrunUNKNOWN French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Francophone de la Sclérose En Plaques (SF
Jun 3, 2021·Advances in Therapy·Patricia K CoyleScott D Newsome
Aug 28, 2021·Pharmacology & Therapeutics·Emanuela Colombo, Cinthia Farina
Oct 24, 2021·Annals of Neurology·Emma C TallantyreRuth Dobson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Related Papers

Clinical Immunology : the Official Journal of the Clinical Immunology Society
Trina A JohnsonJack Antel
Current Neurology and Neuroscience Reports
Vijayshree Yadav, Dennis Bourdette
Clinical Pharmacokinetics
Olivier J DavidRobert Schmouder
© 2021 Meta ULC. All rights reserved